Check out Komipharm, a COVID-related stock with strong government support!

- Found the same material as Komipharm dot up! Government support received upupup!

- Full-scale development of COVID-19 vaccine! Which company has a pandemic vaccine facility fully equipped?

◈ Found the biggest beneficiary stock of COVID-19! Time to quickly buy Komipharm same material! ▶3-day free application◀

Research and development have begun to secure a vaccine manufacturing technology platform that can be quickly applied in the event of a new infectious disease pandemic. Based on the technology developed for respiratory disease prevention vaccines such as quadrivalent cell-cultured influenza vaccine and 13-valent pneumococcal protein conjugate vaccine, they aim to respond to new infectious diseases.

◈ Started development of a new drug that can cure COVID-19 100%! If a globally distributable vaccine comes out, dot up! ▶3-day free application ◀

The core of the platform technology is to have universality that can quickly succeed in vaccine development through the same process even if a new variant virus of respiratory infectious disease appears, and to have high safety considering highly pathogenic viruses.

◈ Vaccine development for respiratory infectious diseases speeds up with the same process! If "this" comes out, it goes dot up! ▶ Click here ◀

While the domestic pharmaceutical bio industry, which had been struggling, is expected to show signs of recovery in the second half of this year, some stocks that had remained silent despite favorable factors are re-emerging, presenting a golden opportunity to aim for a life turnaround.

◈ Will you just watch again? You must sweep up with COVID-19 now! Try investing even 1 million won! ▶3-day free application◀

※ Limited to the first 10 applicants! Recruiting the hero of the 9th inning, 2 outs, walk-off grand slam ※

※ Limited to the first 10 applicants! Please understand early closure due to overwhelming applications. ※

[Today's stocks of interest]

Wellcron Komipharm SY Hanjin Kal Cheil Bio

※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.